How does Alnylam Pharmaceuticals (ALNY) make money?

Alnylam Pharmaceuticals (ALNY) generates revenue primarily from Product, which accounted for 78.8% of total revenue in TTM through Q1 2026. The company reported $4.29B in revenue and converted 13.5% of it into net profit, equivalent to roughly $577M in net income — what's left after the cost of revenue, operating expenses, interest, and income taxes.

What is the gross profit margin of Alnylam Pharmaceuticals (ALNY)?

Alnylam Pharmaceuticals (ALNY) reported a gross profit margin of 80.9% in TTM through Q1 2026, equivalent to $3.47B in gross profit on $4.29B in revenue. Gross margin measures how much of each dollar of revenue remains after the direct cost of producing or delivering the product — a higher figure typically signals pricing power, scale, or a less capital-intensive business model.

What is the operating profit margin of Alnylam Pharmaceuticals (ALNY)?

Alnylam Pharmaceuticals (ALNY) reported an operating profit margin of 17.5% in TTM through Q1 2026, equivalent to $752M in operating income. Operating margin captures profitability after research & development, sales & marketing, and general & administrative expenses — but before interest, taxes, and one-off items — and is the cleanest single read on the underlying business's efficiency.

What is the net profit margin of Alnylam Pharmaceuticals (ALNY)?

Alnylam Pharmaceuticals (ALNY) reported a net profit margin of 13.5% in TTM through Q1 2026, equivalent to $577M in net income. Net margin is the bottom-line share of revenue that survives every expense — operating costs, interest, and income taxes — and is the figure that flows directly into earnings per share.

Is Alnylam Pharmaceuticals (ALNY) profitable?

Yes. Alnylam Pharmaceuticals (ALNY) reported $577M in net income for TTM through Q1 2026, with a net profit margin of 13.5%. The company earned more from its operations than it paid out in costs, interest, and income taxes, leaving positive earnings on the bottom line.

How much does Alnylam Pharmaceuticals (ALNY) invest in research and development?

Alnylam Pharmaceuticals (ALNY) invested $1.42B in research and development during TTM through Q1 2026, roughly 33.1% of total revenue. R&D spending funds the company's future product pipeline and is expensed in full on the income statement rather than capitalised, which makes the operating margin sensitive to how aggressively management chooses to reinvest in innovation.

How much does Alnylam Pharmaceuticals (ALNY) spend on capital expenditures?

Alnylam Pharmaceuticals (ALNY) spent $71.6M on capital expenditures (CapEx) during TTM through Q1 2026, roughly 1.7% of total revenue. CapEx represents long-lived investment in property, equipment, data centres, and other physical infrastructure, and is subtracted from operating cash flow to arrive at free cash flow.

How much free cash flow does Alnylam Pharmaceuticals (ALNY) generate?

Alnylam Pharmaceuticals (ALNY) generated $641M in free cash flow during TTM through Q1 2026, a free-cash-flow margin of 15.0%. Free cash flow is the cash left after capital expenditures and represents the discretionary pool the company can use to pay dividends, repurchase shares, repay debt, or fund acquisitions without raising external capital.

What are the main business segments of Alnylam Pharmaceuticals (ALNY)?

Alnylam Pharmaceuticals (ALNY) reports revenue across 3 reportable product segments, led by Product at 78.8% of total revenue in TTM through Q1 2026. See the revenue-by-segment table on this page for the full breakdown and how each segment feeds into the income-statement waterfall above.

How Alnylam Pharmaceuticals Makes Money: 2026 Visual Revenue Map

Alnylam Pharmaceuticals (ALNY) Income Statement Flow — TTM through Q1 2026

Calculated from the four most recent reported quarters, ending March 31, 2026 (reported April 30, 2026).

Alnylam Pharmaceuticals discloses geographic revenue only in annual filings. to view the full breakdown.

Alnylam Pharmaceuticals (ALNY) Revenue by Product Segment — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported segments changed mid-year.

Revenue contribution by product segment for Alnylam Pharmaceuticals (ALNY), TTM through Q1 2026.
Segment	Revenue (USD)	% of total
Product	$3.38B	78.8%
GIVLAARI	$625M	14.6%
ONPATTRO	$284M	6.6%
Total	$4.29B	100%

Product$3.38B
GIVLAARI$625M
ONPATTRO$284M
Total$4.29B

Revenue Breakdown — TTM through Q1 2026

In TTM through Q1 2026, Alnylam Pharmaceuticals (ALNY) reports revenue across 3 reportable product segments; the largest segment was Product at 78.8%, followed by GIVLAARI (14.6%) and ONPATTRO (6.6%).

Frequently asked questions

Data & methodology

Alnylam Pharmaceuticals (ALNY) Key Financials

Charts, filings, and peer comparison for every metric

Trains Company Knowledge

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview

ALNY Overview

Counters

Income Statement

Cash Flow

Capital Return

Buybacks

How this company returns cash to shareholders — buybacks, dividends, and stock splits.

Forecast & Valuation